Sentien Biotechnologiesincis A Clinical Stage Biotechnology Company Based In Lexingtonmathe Company Focuses On Developing Innovative Cell Therapies Aimed At Treating Acute Inflammatory Diseaseswith A Team Of 11Ae 50 Professionalssentien Operates As A Privately Held Entity The Company Specializes In Extracorporeal Cell Therapy Platforms That Modulate The Immune Systemtheir Flagship Productsbi 101Is An Extracorporeal Device That Immobilizes Mesenchymal Stromal Cellsmscsto Deliver Controlled Doses Of Anti Inflammatory And Regenerative Factors Directly Into A Patientae S Bloodstreamthis Approach Targets High Mortality Conditions Such As Sepsis Induced Acute Kidney Injury And Complications From Covid 19Including Acute Respiratory Distress Syndrome Sentien Collaborates With Organizations Like The Biomedical Advanced Research And Development Authority And The Maryland Stem Cell Research Fundthey Have Completed Phase 1 2 Enrollment For Severe Covid 19 Trials And Are Advancing Studies For Sepsis Akithe Company Has Received Fda Investigational New Drug Clearance For Sbi 101 In Covid 19Reflecting Its Commitment To Addressing Critical Care Needs
